SCHEMBL10189923

SCHEMBL10189923

CSC(=S)OCc1nnc(C2CCN(C(=O)OC(C)(C)C)CC2)n1-c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
USP2 O75604 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TP53 P04637 6/20 0.44
MAPT P10636 3/20 0.44
THRB P10828 2/20 0.44
GPR119 Q8TDV5 1/20 0.42
POLB P06746 1/20 0.42
KDM1A O60341 1/20 0.41
STS P08842 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8255797 0.86 MEN1 (0.52) LMNAMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL8285418 0.84 MEN1 (0.53) LMNAMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL315881 0.80 MEN1 (0.52) LMNAMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL10189899 0.79 MEN1 (0.56) LMNAMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL8285085 0.78 THRB (0.48) LMNAMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL315796 0.74 OXTR (0.45) MEN1KMT2ANPSR1ALDH1A1USP2
SCHEMBL10189920 0.71 GPR119 (0.52) LMNASMN1; SMN2GAATP53MAPT
SCHEMBL314703 0.69 AVPR1A (0.43) MEN1KMT2ANPSR1ALDH1A1USP2
SCHEMBL8310737 0.69 NAMPT (0.60) LMNAMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL8285088 0.69 CNR1 (0.51) LMNAMEN1KMT2ANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-7745630-B2 Triazolyl piperidine arginine vasopressin receptor modulators BRYANS JUSTIN STEPHEN 2010-06-29 US disclosed
US-7745630-B2 Triazolyl piperidine arginine vasopressin receptor modulators BRYANS JUSTIN STEPHEN 2010-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317652-A1 Compounds Useful In Therapy AVPR1A, AVPR1B, AVPR2 LMNA 1738/4885MEN1 1081/4885KMT2A 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.